Researchers at Washington University School of Medicine in St. Louis report that blocking a protein called CXCR3 with an antibody reduced the number of T cells in the brains of mice with tau accumulation and protected brain tissue from damage. After several months of treatment, the animals had about half as many T cells in their brains as untreated mice, retained roughly 40% more tissue in memory-related regions, and did better on a memory test. The amount of tau in their brains did not change.
The work builds on earlier findings from David M. Holtzman's laboratory. A 2023 study in Nature showed that T cells enter the brains of mice with abnormal tau and concentrate where tau is heaviest, where they contribute to neurodegeneration. The team then traced the route these cells take. Mice lacking either the chemical signal CXCL10 or its receptor CXCR3 on T cells were protected from T cell infiltration, even when inflammation was deliberately triggered.
Current Alzheimer's drugs, lecanemab and donanemab, target amyloid and can slow cognitive decline, but the source notes they have not been shown to stop brain cells from dying. They also offer nothing for primary tauopathies, where tau builds up without amyloid. That gap is why the researchers see the immune pathway as worth pursuing.
A notable detail is that the antibody reached the boundary of the brain but did not enter brain tissue. If the approach proves safe, it could act on immune activity from outside the brain, sidestepping the blood-brain barrier that keeps many drugs out. Holtzman also suggested that drugs already used to control T cells in multiple sclerosis and other autoimmune conditions could be worth testing.
These results come from mice only. The authors state that further research is needed to determine whether the approach is safe and effective enough to test in people.